Thank you for submitting your manuscript for consideration by EMBO Molecular Medicine. It has now been seen by three referees whose comments are shown below.
1. Splicing alterations refer mainly to exon inclusions; no deletion of functional protein domain should be caused by these alterations. How exon inclusion may cause modification/alteration of protein functions and how cholinergic neurons could be specifically involved? These points should be properly discussed. 2. The data reported in fig 5 show that a cholinergic toxin brings about a reduction of hnRNP A/B. Would toxin specific for other neurons in other brain areas (e.g. dopaminergic neurons) have similar effect? 3. How the lower level of AChE (fig 4G) in the medium of hnRNP knock-down cultured neurons can be related to the known AD cholinergic deficit? Is AChE retained on the cell surface due to alternative splicing or the total level of the enzyme is lower? Cell associated activity should also be reported and how the AChE activity variation is related to AD cholinergic deficit should be discussed. 4. Fig.2A . Cells should be evident in all frames in order to evaluate the loss of hnRNP in AD sample. No cells can be clearly appreciated in the frames of AD samples, even in the high magnification inset. SR and hnRNP should stain all cells; a much lower number of cells appear stained for hnRNP as compared to SR. Is this due to differences in the samples? 5. Fig 4. The reported immunostaining demonstrate reduction of dendrites, which certainly results in a lower number of synapses; if dendrites are reduced in number one would expect lower staining for synaptophysin. However synaptophysin staining cannot be taken as evidence of synapse formation, being associated to presynaptic vesicles and not to presynaptic membranes; evaluation of synapse formation would require the use of more appropriate markers, as e.g. syntaxin and SNAP 25 or electron microscopy analysis. Furthermore, although the AA exclude significant cell death, dendritic coverage reported in D should be normalized to cell number (DAPI stained nuclei) for a more accurate evaluation. The technical quality is low because authors perform a screening using a most heterogeneous mix of samples. The novelty is medium because an early paper has shown that the hnRNP A plays a role in the control of ApoE transcription, an event that authors ignore and could be highly relevant to their findings (in their most heterogeneous starting material many cases are ApoE4, a known risk factor for AD). The medical relevance is low because authors claim that increasing hnRNP A/B may be a valid strategy for therapeutics yet the changes observed occur in very late AD , with severe signs of brain degeneration (Braak V and Braak VI) and therefore with abundant neuronal death. The experimental models used to test the observation from the micro array are valid. It is not valid the type of material used for the microarray study Referee #2 (Other Remarks):
To identify transcriptional changes that could lead to AD, Berson and colleagues applied exon-level micro-array analysis on post-mortem EC from AD patients and controls. This study led to the identification of 383 exons with significantly different exon inclusion, corresponding to 319 genes. As expected, these genes play a role in numerous and diverse pathways, including RNA-binding which is the issue of interest for these investigators. In that sense, authors focussed their attention in the heterogeneous nuclear ribonuclearproteins (hnRNPs) A/B which appeared strongly downregulated in the EC of AD patients. Consistent with a possible functional relevance, in vivo shRNA downregulation led to an impairment in certain learning and memory aspects of mice, disturbed network activity, reduced synaptic density and acetylcholinesterase activity. Interestingly, the while amyloid and tau pathology were not accompanied by decreased hnRNPA/B this was the case in mice with reduced cholinergic neurons. Despite some interesting aspects, especially in relation to the effect of hnRNP A/B downregulation in mice, I find this work too preliminary for acceptance at EMBO Molecular Medicine.
Critique 1) Authors have used a most heterogeneous sample group to elucidate transcriptional changes: 1) AD individuals with age range between 57 to 90, therefore mixing cases of familial with sporadic, 2) non AD individuals with a similar heterogeneous range of age, 3) individuals with severe and late degeneration/dementia, with Braak pathology ranging from V to VI and 4) AD cases with different combinations of ApoE genotype. In order to make the findings relevant for a possible "causative" role (and therefore re-elevation of hnRNP A/B as possible therapeutics) authors need to "group" the samples, into brains of individuals with similar Braak (I-II, III-IV, V-VI), within a similar age range (75-80, 80-85, 85-90) , with the same ApoE genotype (or at least with and without ApoE4) and with a known previous health status, so to exclude/include the possible influence of peripheral or central pathology (i.e. type II diabetes, hypercholesterolemia, stroke). I need to see whether downregulation is an early or late event, typical of ApoE 4 or independently from it, accompanying cases that had been preceded by systemic pathology or not. 2) Authors need to show the pattern of labelling of brain of different AD-affected individuals. Does the image shown in Figure 2 A and 2 B equally account for 87 year old with Braak VI, a 57 year old with Braak VI and 65 year old? Authors also need to show the staining in a Braak III, for example, still lacking massive degeneration. 3) From how many patients and of which characteristics (in terms of age, degree of degeneration and ApoE genotype) is the SDS extract used for the westerns of Figure 2C -E? Authors need to show the pattern for the different groups. 4) How is the pattern of expression of hnRNPA/B in the entorhinal cortex of individual/s affected by another pathology (i.e. stroke) ? This type of control is required to be able to propose disease specificity. Lack of downregulation in the subsantia nigra of Parkinson's individuals simply says that Parkinson is not accompanied by hnRNA A/B downregulation but not that AD is. It still can be that this is a hippocampal/EC characteristic, due to any other type of pathology. 5) The correlation with the ApoE4 genotype is most relevant. Previous work has demonstrated the importance of hnRNPA1 in ApoE promoter activity (Campillos et al., 2003) . It suggests to me that some of the changes in expression here reported may be linked to the ApoE genotype. 6) Authors need to show how reduced hnRNP A/B affects APP processing. Since over-expression induces alternative splicing of APP mRNA, followed by reduced Abeta production, it appears most essential to show if the opposite occurs upon down-regulation, as the authors seem to favour in Discussion. 7) Authors should not use actin to normalize loading, due to the fact that neurite formation is reduced in shRNA knocked down cells and therefore actin synthesis can increase to compensate poor growth. A cytosolic, growth-unrelated (i.e. a survival) or a nuclear membrane structural protein may be better normalization loading controls. 8) Authors need to test the effect of hnRNP A/B downregulation in relation to glutamatergic activity. Some of the behavioural defects observed are consistent with a perturbation in glutamatemediated activity. Moreover, many previous studies have shown glutamatergic transmission defects in the synaptopathy of AD. 9) Because of hnRNA A/B downregulation seems to be a late event in AD (most of cases utilized for the screening have profound degeneration) and because this is induced upon the induction of cholinergic neuronal loss, authors have little ground to conclude that re-elevation of hnRNP can be a valid therapeutical strategy for AD. This needs to be, minimally, toned down.
Referee #3 (Other Remarks):
In this manuscript Berson and collaborators investigate the role of hnRNP A/B proteins in splicing defects in entorhinal cortices of patients with sporadic Alzheimer's disease (AD). They show that hnRNP A/B knockdown induces dendrite and synapse loss in primary neurons and elctrocorticographic impairments in mice. In addition, the expression of hnRNP A/B in primary neurons is induced after cholinergic excitation while in vivo neurotoxin-mediated destruction of cholinergic neurons causes cortical AD-like decrease in hnRNP A/B and recapitulates alternative splicing patterns in DA patients. Comment Novelty: This is an very interesting manuscript that investigates the so far underestimated role of alternative splicing (AS) in sporadic AD. In addition to provide a complete picture of alteration in AS profiles, the authors perform a number of experiment in mouse and identify hnRNP A/B as the splicing factors involved. Finally they create a link between the expression of these proteins and cholinergic signaling. Thus, the manuscript significantly increases our comprehension of this important pathology and open a new perspective for therapy. Major concern: The authors should perform appropriate controls to corroborate their interpretations and conclusions about the role of hnRNP proteins in splicing defects. Specific points. 1 -They find that 75% of the alterations in AS profiles observed in sporadic AD correspond to increased exon inclusion. It would be nice to know the level of concordance between the 3 analyzed patients. Has each patient a specific set of alterations compare to controls. Can the author quantify the variability between control individuals? 2 -No alterations in the level of SR factors is detectable. In contrast the authors observe an almost complete loss of hnRNP A/B proteins. Interestingly, in figure 2B it is evident that an important fraction of nuclei are not recognized by anti hnRNP A/B antibodies also in control specimens. Moreover, it appears that the expression of SR protein in AD samples is restricted to neurons with massive tangle morphology. Can the authors comment on this aspect? 3 -In Figure 3B the authors investigate the effect of hnRNP A/B downregulation on learning and memory performance in mice. To this, they inject shRNA viruses to the enthorhinal cortex of C57/B6 mice. The same shRNA were proven to be efficient in hnRNP A/B downregulation in mouse primary mixed cortical cultures. However, no evidence (Western blotting or Immunofluorescence) is given about their efficacy in vivo. 4 -The authors should investigate the effect of hnRNP A/B depletion on the alternative splicing profile of selected genes as in Figure 1 and 5. This is important to better understand the experiments in Figure 5 . Moreover, to substantiate the role of hnRNP A/B proteins in the alterations of AS profiles they should experimentally prove the interaction of these proteins with target RNAs. Minimally they should identify possible binding sites by in silico analysis. 5 -The authors investigate the effect of mutated Tau on the expression of hnRNP A/B-On the basis of Western and Immunofluorescence analysis they conclude that a mutation known to produce tau pathologies does not affect hnRNP A/B expression. One should conclude that the expression of the mutated Tau does not complete mimics the pathological status. However, it is evident from Figure  5B that the fraction of cell nuclei that are not stained by antibodies against hnRNP A/B is reduced in cell expressing mutated tau compared to controls. Can the authors comment on these aspects? 6 -Finally, the authors consider the fact that AD brains are characterized by cholinergic defects (from point 5 we should assume that a cholinergic defect is not induced upon expressing mutated Tau). They induce in vivo loss of function by destroying cholinergic neurons. It is unclear to me if this treatment affects only the expression of hnRNP A/B or other splicing factors as well. Moreover, the effect of these treatments on the expression of hnRNP proteins appears more modest than that observed in patients (compare the histogram in panel 5C with those in panel 2C). It would be nice to see whether the same alterations in AS profiles observed after pharmacological treatments do occur in mice after down-regulation of hnRNP A/B proteins.
Rebuttal
14 November 2011 I would respectfully like to ask you to reconsider your decision not to accept our paper for possible revision. We find it difficult to classify referee #1 as a negative review when he states "The manuscript address a very interesting problem, data are clearly presented and the relation between RNA metabolism modifications and cholinergic neuron impairment are well documented." The points which he states as "worth of further attention" are not problems which are critical to the core of the paper and we believe can be easily addressed in a revised manuscript. Although referee #2 does make significant criticisms we believe that these issues, although important, can be addressed as well. Reviewer 3 is very positive regarding the significance of our findings and states that "the manuscript significantly increases our comprehension of this important pathology and opens a new perspective for therapy".
We agree that Referee # 2 was significantly more negative but still believe that given the chance to significantly revise the paper we can deal with his objections. His major criticism was the heterogeneous nature of the patient population but we believe that this may be one of this study's strengths. Rather than using an artificial inbred mouse model, we dealt with the real thing-diseased brain tissues, and nevertheless found significant differences. Any biological effect that is seen in spite of age and gender variability would be more likely to be important in the pathogenesis of the disease. Also, although the specific critiques listed by this referee are significant, we believe we could satisfactorily address them in a revision. The referee's issue of hnRNP reduction being a relatively late event and thereby of limited therapeutic value is accepted by us and will be addressed in the revised manuscript; since this paper was submitted, we analyzed early Alzheimer's transcriptomes and found early changes in alternative splicing, which we will be happy to include in the revised manuscript. Additionally, our findings use new techniques to show a novel and important aspect of disease pathogenesis which would be of interest to many. Based on all of this, we respectfully argue that answering the reviewers' criticism should improve the value of our paper substantially and may justify publication of this paper in EMBO medicine.
Again we request that you reconsider your decision about the manuscript and allow us the chance to resubmit with major revision.
Editorial Correspondence 14 November 2011
Thank you for your recent letter asking us to re-consider our decision. After reading your letter and discussing again with my colleagues, I would like to give you the opportunity to revise your work considering the points below.
Given that our main concern was the limited clinical relevance highlighted by 2 referees and particularly developed by referee 2, providing now additional data validating hnRNP A/B loss in early AD patients would increase the medical impact. So please do include this new data to your revised manuscript.
In addition, I would like to emphasize important criticisms that must be addressed:
-Please provide a multi-factorial analysis of your heterogeneous samples. I do not think that the reviewer #2 had mice models in mind with his comment, but rather implied that comparing patients that are not comparable could bias the result of your analysis. For this reason, using smaller more homogeneous groups (like age, brain degeneration, sporadic vs. familial AD, ApoE and health status) should not change the overall outcome of your analysis but rather results in stronger correlations and better p-values.
-Please clarify the ApoE4 status of the samples used and discuss the paper from Campillos et al 2003.
-Strengthening your manuscript mechanistically speaking would also be desirable.
Please be reminded that it is EMBO policy to ask for a single major revision. I must stress however, that the referees' concerns must be fully addressed and that acceptance of the manuscript would entail a second round of review. Therefore I would encourage you to respond to all criticisms as satisfactorily as possible.
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline (precisely as we do anticipate a large amount of work to respond to all criticisms), please let us know in advance and we may be able to grant an extension.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website.
I look forward to seeing a revised form of your manuscript as soon as possible.
Should you find that the requested revisions are not feasible within the constraints outlined here and choose, therefore, to submit your paper elsewhere, we would welcome a message to this effect. The data presented are of interest for a better understanding of mechanism leading to AD; therefore they have an indirect medical impact.
Yours sincerely,

Editor EMBO Molecular Medicine
Referee #1 (Other Remarks):
Data reported in this work show alterations of RNA metabolism, leading to impairment of exon exclusion; selective loss of hnRNP A/B splicing factors is reported. The modifications of RNA metabolism have been observed in cortex samples of AD patients and confirmed in neuron primary cultures after specific destruction of cholinergic neurons. In addition to the RT-PCR and real time RT-PCR analysis showing the splicing alterations, the selective loss of hnRNP A/B in AD patient cortex has been analysed by immunocytochemistry. The relevance of hnRNP A/B tocortical function has also been studied in hnRNP A/B KO mice and the relation of hnRNP A/B expression and cholinergic function considered.
The manuscript address a very interesting problem, data are clearly presented and the relation between RNA metabolism modifications and cholinergic neuron impairment is well documented. However some points are worth of further attention by the AA.
Splicing alterations refer mainly to exon inclusions; no deletion of functional protein domain should be caused by these alterations. How exon inclusion may cause modification/alteration of protein functions and how cholinergic neurons could be specifically involved? These points should be properly discussed.
We appreciate this comment, as it highlights an important point that we neglected to mention and discuss. As a matter of fact, exon inclusion can and does cause modifications of protein functions, specifically in cholinergic neurons. We would like to use the acetylcholinesterase (AChE) mRNA transcript as an example. Inclusion of the extended exon 4 domain encoding the C-terminus which is unique to the "readthrough" AChE-R variant replaces the otherwise prevalent C-terminus which enables membrane binding of the "synaptic" AChE-S variant, with functional consequences in stress (Kaufer, Nature 1998; Meshorer, Science 2002) and Alzheimer's disease (Berson, Brain 2008) . As this transcript is expressed in cholinergic brain neurons at 100-fold higher levels than in other neurons (Soreq and Seidman, Nature Neuroscience Reviews 2001), such an inclusion is likely to exert functionally important changes on cholinergic neurons. This explanation has been added to the relevant text sections in the revised article.
The data reported in fig 5 show that a cholinergic toxin brings about a reduction of hnRNP A/B. Would toxin specific for other neurons in other brain areas (e.g. dopaminergic neurons) have similar effect?
This is an interesting comparison. That we found no decline in hnRNP A/B in the substantia nigra from brains of Parkinson's disease patients argues against this option. Also, in another recent work, we have analyzed Transcriptome changes in brain regions of mouse models with different dopaminergic impairments. While the data available to us was only of 3'-arrays, learning algorithms showed mitochondrial and nuclear transcription, rather than exon inclusion as the affected processes (Soreq, L. et al., Neurobiology of Disease 2012). (fig 4G) in the medium of hnRNP knockdown cultured neurons can be related to the known AD cholinergic deficit? Is AChE retained on the cell surface due to alternative splicing or the total level of the enzyme is lower? Cell associated activity should also be reported and how the AChE activity variation is related to AD cholinergic deficit should be discussed.
How the lower level of AChE
The known AD-related cholinergic deficit involves premature malfunctioning and early death of cholinergic neurons, which produce 100-fold higher levels of AChE than any other cell type in the brain. The total level of the enzyme is lower, and in particular the levels of the secreted enzyme variant decline sharply (Berson et al., Brain 2008) . Given the space limitations of EMBO Molecular Medicine we refrained from repeating this information in the current paper.
4. Fig.2A . Cells should be evident in all frames in order to evaluate the loss of hnRNP in AD sample. No cells can be clearly appreciated in the frames of AD samples, even in the high magnification inset. SR and hnRNP should stain all cells; a much lower number of cells appear stained for hnRNP as compared to SR. Is this due to differences in the samples?
To address this comment, we expanded Fig. 2 to include more samples. We have also increased the quality of the micrographs so that cells are clearly visible. The apparent lack of cells in the previous version resulted from the loss of hnRNP staining and so without background staining this may appear as reduced number of cells. However, the staining of SR proteins in the exact same anatomical location in subsequent slices from the same patients clearly showed that cells are present in these photomicrographs.
5. Fig 4. The reported immunostaining demonstrate reduction of dendrites, which certainly results in a lower number of synapses; if dendrites are reduced in number one would expect lower staining for synaptophysin. However synaptophysin staining cannot be taken as evidence of synapse formation, being associated to presynaptic vesicles and not to presynaptic membranes; evaluation of synapse formation would require the use of more appropriate markers, as e.g. syntaxin and SNAP 25 or electron microscopy analysis. Furthermore, although the AA exclude significant cell death, dendritic coverage reported in D should be normalized to cell number (DAPI stained nuclei) for a more accurate evaluation.
Thank you for this important comment. The word "synapses" was replaced by "synapse-like structures" and the dendritic coverage reported in D has been normalized to cell numbers as requested and the numbers corrected in the manuscript accordingly. All corrected as commented. Thanks for drawing our attention to these errors.
Referee #2 (Comments on Novelty/Model System):
The technical quality is low because authors perform a screening using a most heterogeneous mix of samples. The novelty is medium because an early paper has shown that the hnRNP A plays a role in the control of ApoE transcription, an event that authors ignore and could be highly relevant to their findings (in their most heterogeneous starting material many cases are ApoE4, a known risk factor for AD). The medical relevance is low because authors claim that increasing hnRNP A/B may be a valid strategy for therapeutics yet the changes observed occur in very late AD, with severe signs of brain degeneration (Braak V and Braak VI) Critique 1) Authors have used a most heterogeneous sample group to elucidate transcriptional changes: 1) AD individuals with age range between 57 to 90, therefore mixing cases of familial with sporadic, 2) non AD individuals with a similar heterogeneous range of age, 3) individuals with severe and late degeneration/dementia, with Braak pathology ranging from V to VI and 4) AD cases with different combinations of ApoE genotype. In order to make the findings relevant for a possible "causative" role (and therefore re-elevation of hnRNP A/B as possible therapeutics) authors need to "group" the samples, into brains of individuals with similar Braak (I-II, III-IV, V-VI), within a similar age range (75-80, 80-85, 85-90) , with the same ApoE genotype (or at least with and without ApoE4) and with a known previous health status, so to exclude/include the possible influence of peripheral or central pathology (i.e. type II diabetes, hypercholesterolemia, stroke) . I need to see whether downregulation is an early or late event, typical of ApoE 4 or independently from it, accompanying cases that had been preceded by systemic pathology or not.
Thank you for this request, in response to which we doubled the number of tested patients and controls, and performed multi-factorial statistics as requested on the expanded set of samples. We were satisfied to learn from this analysis that the major factor affecting the depletion of hnRNPs in the entorhinal cortex is the disease itself, and more specifically-the cognitive decline associated with the disease; regardless of age, gender or ApoE genotype. These new samples and analysis have now been described in the text and the revised supplementary material.
2) Authors need to show the pattern of labelling of brain of different AD-affected individuals. Does the image shown in Figure 2 A and Indeed, patients with diverse demography show the same pathology, as is now demonstrated in an expanded selection of photomicrographs which is presented in Figure 2 . We further detailed the demographic criteria of each of these patients in a supplementary file. Also, we revised figure 3 and Supplementary Fig. 3 where we present the outcome of the new immunoblots, adding those of Braak III patients without cognitive decline. In these patients the depletion of hnRNPs was minimal, suggesting an association of the hnRNP A/B decline with the cognitive, rather than the amyloid neuropathology of the patients. Of note, this is compatible with our recent meta-analysis of high throughput datasets from AD patients at different disease stages (Barbash and Soreq, Current Alzheimer's Research 2012).
3) From how many patients and of which characteristics (in terms of age, degree of degeneration and ApoE genotype) is the SDS extract used for the westerns of Figure 2C -E? Authors need to show the pattern for the different groups.
In this case as well, we enlarged the set of analyzed immunoblots and added the clinical details and immunoblots to supplementary files and a new supplementary figure. The patterns for the different age, gender and ApoE genotype groups were essentially similar, as shown by the accompanying statistics.
4)
How is the pattern of expression of hnRNPA/B in the entorhinal cortex of individual/s affected by another pathology (i.e. stroke)? This type of control is required to be able to propose disease specificity. Lack of downregulation in the subsantia nigra of Parkinson's individuals simply says that Parkinson is not accompanied by hnRNA A/B downregulation but not that AD is. It still can be that this is a hippocampal/EC characteristic, due to any other type of pathology.
To re-explore the disease specificity and the cell type variability of our findings we approached Prof Albert J. Becker of Bonn University, who specializes in the study of epilepsy. Dr Becker provided us with a set of live-extracted brain sections that were removed at surgery from a sclerotic tissue in a parallel brain region of epileptic patients, as an independent control. Immuno-labeling of these sections highlighted intensely labeled and densely distributed hnRNP A/B-positive neuronal nuclei. Together with our previous observations, this experiment emphasized the specificity of the hnRNP A/B depletion for Alzheimer's disease, but not Parkinson's disease or epilepsy. The corresponding micrographs were added to Figure 2 , and Prof Becker joined us as a co-author.
5)
The correlation with the ApoE4 genotype is most relevant. Previous work has demonstrated the importance of hnRNPA1 in ApoE promoter activity (Campillos et al., 2003) . It suggests to me that some of the changes in expression here reported may be linked to the ApoE genotype.
Thank you for drawing our attention to this interesting phenomenon, which is now referred to with a citation of the Campillos study in the revised manuscript. In our current study, the ApoE genotyping and multi-factorial analysis for the expanded cohort demonstrated no correlation between the observed depletion of hnRNP A/B in Alzheimer's disease and the ApoE genotype (1-4) of the tested volunteers. The corresponding data had been inserted both for the patients' cohort and the control samples. Further, we re-examined the possibility of hnRNP A1 regulation by the -219T/G polymorphism in the ApoE promoter as published by Campillos et al., 2003 . Genotype analysis supplemented by quantitative RT-PCR measurements showed no correlation whatsoever between this polymorphism and the hnRNP A/B decline which we disclose in this study.
6) Authors need to show how reduced hnRNP A/B affects APP processing. Since over-expression
induces alternative splicing of APP mRNA, followed by reduced Abeta production, it appears most essential to show if the opposite occurs upon down-regulation, as the authors seem to favour in Discussion.
Using RT-PCR tests for the different alternative splice variants of APP transcripts, we found that the exon for the KPI isoform is preferentially included in the AD patient samples. Parallel findings were reported by others (see Matsui, T. et al 2007 Brain Research, which has now been cited in the revised manuscript). This information has been added to the supplementary data and the discussion amended.
7)
Authors should not use actin to normalize loading, due to the fact that neurite formation is reduced in shRNA knocked down cells and therefore actin synthesis can increase to compensate poor growth. A cytosolic, growth-unrelated (i.e. a survival) or a nuclear membrane structural protein may be better normalization loading controls.
Given that most studies that we have inspected use tubulin as a loading marker for normalizing protein amounts, we included tubulin labeling as a loading control in our new set of immunoblots, with essentially the same result as those with actin.
8) Authors need to test the effect of hnRNP A/B downregulation in relation to glutamatergic activity.
Some of the behavioral defects observed are consistent with a perturbation in glutamate-mediated activity. Moreover, many previous studies have shown glutamatergic transmission defects in the synaptopathy of AD.
We absolutely agree and added a note to that effect to the revised text. Given that up to 90% of the brain's synaptic activity is glutamatergic, our data of impaired electroencephalography recordings in the lentivirus-injected mice reflect glutamatergic activity changes under hnRNPs depletion.
9) Because of hnRNA A/B downregulation seems to be a late event in AD (most of cases utilized for the screening have profound degeneration) and because this is induced upon the induction of cholinergic neuronal loss, authors have little ground to conclude that re-elevation of hnRNP can be a valid therapeutical strategy for AD. This needs to be, minimally, toned down.
Toned down as requested. That AD is currently diagnosed late in the disease process naturally limits therapeutic strategies to this stage. Therefore, this argument is obviously correct also for the amyloid processing blockers that are currently being developed for treating AD; at present, ANY therapeutically effective strategy would be a step forward.
Referee #3 (Other Remarks):
In this manuscript Berson and collaborators investigate the role of hnRNP A/B proteins in splicing defects in entorhinal cortices of patients with sporadic Alzheimer's disease (AD). They show that hnRNP A/B knockdown induces dendrite and synapse loss in primary neurons and elctrocorticographic impairments in mice. In addition, the expression of hnRNP A/B in primary neurons is induced after cholinergic excitation while in vivo neurotoxin-mediated destruction of cholinergic neurons causes cortical AD-like decrease in hnRNP A/B and recapitulates alternative splicing patterns in DA patients.
Comment
Novelty: This is an very interesting manuscript that investigates the so far underestimated role of alternative splicing (AS) in sporadic AD. In addition to provide a complete picture of alteration in AS profiles, the authors perform a number of experiment in mouse and identify hnRNP A/B as the splicing factors involved. Finally they create a link between the expression of these proteins and cholinergic signaling. Thus, the manuscript significantly increases our comprehension of this important pathology and opens a new perspective for therapy. Major concern: The authors should perform appropriate controls to corroborate their interpretations and conclusions about the role of hnRNP proteins in splicing defects.
Specific points.
-They find that 75% of the alterations in AS profiles observed in sporadic AD correspond to increased exon inclusion. It would be nice to know the level of concordance between the 3 analyzed patients. Has each patient a specific set of alterations compare to controls. Can the author quantify the variability between control individuals?
A group of three is too small for elaborate statistics, but nevertheless the differences in exon inclusion events were statistically significant between the three patients and three controls. Although arguing that a specific gene is alternatively spliced based on 3 on 3 arrays would be of a low statistical power, arguing that most genes undergo a change in the same direction requires a groupto-group comparison that enables a smaller sample size. The variability between the controls, based on the splicing index for all identified exons, was 1.5 fold higher than the variability between the patients. This suggests `directionality` in the splicing change induced by the disease. figure 2B it is evident that an important fraction of nuclei are not recognized by anti hnRNP A/B antibodies also in control specimens.
-No alterations in the level of SR factors is detectable. In contrast the authors observe an almost complete loss of hnRNP A/B proteins. Interestingly, in
Moreover, it appears that the expression of SR protein in AD samples is restricted to neurons with massive tangle morphology. Can the authors comment on this aspect?
It is true that hnRNP A/B staining seems stronger in some cell types than in others. This is most likely due to the fact that hnRNP A/B expression is higher in neurons than in glia (Kamma H et al., 1995, Exp Cell Res) . However, when imaging parameters are changed (under strictly similar conditions in all micrographs), some expression can be seen also in these cell types, while the neuronal signal is saturated. Furthermore, SR protein expression is not restricted to neurons with tangle morphology, and is similarly expressed in neurons with no clear pathology. Thus, hnRNP A/B are expressed in neurons and selectively lost in AD while SR proteins serve as a control and show no such alteration. We also observed seemingly normal expression of hnRNP A/B expression in sclerotic hippocampus sections extracted at surgery from epilepsy patients, further demonstrating the specificity of our findings. Figure 3B the authors investigate the effect of hnRNP A/B downregulation on learning and memory performance in mice. To this, they inject shRNA viruses to the enthorhinal cortex of C57/B6 mice. The same shRNA were proven to be efficient in hnRNP A/B downregulation in mouse primary mixed cortical cultures. However, no evidence (Western blotting or Immunofluorescence) is given about their efficacy in vivo.
-In
In response to this comment, we performed the requested GFP lentivirus injections into the entorhinal cortex, and quantified the observed fluorescence; this analysis confirmed the correct site of the injection and demonstrated the efficacy of the viral infection as well as the contours of the area where the fluorescence spreads within the injected brains, as is now demonstrated in the revised text and the new supplementary figure 6. Figure 1 and 5. This is important to better understand the experiments in Figure 5 . Moreover, to substantiate the role of hnRNP A/B proteins in the alterations of AS profiles they should experimentally prove the interaction of these proteins with target RNAs. Minimally they should identify possible binding sites by in silico analysis.
-The authors should investigate the effect of hnRNP A/B depletion on the alternative splicing profile of selected genes as in
Thanks for this important comment. We analyzed alternative splicing of several selected transcripts following the knock-down of hnRNP A1, A2/B1 in primary neurons. We now show that this depletion results in increased exon inclusions in 3 alternative exons in the mRNA transcripts of Dystonin, DRAM2 and ApoeR2. This result is included in the new Figure 5 of the revised manuscript.
-The authors investigate the effect of mutated Tau on the expression of hnRNP A/B-On the basis of Western and
Immunofluorescence analysis they conclude that a mutation known to produce tau pathologies does not affect hnRNP A/B expression. One should conclude that the expression of the mutated Tau does not complete mimics the pathological status. However, it is evident from Figure  5B that the fraction of cell nuclei that are not stained by antibodies against hnRNP A/B is reduced in cell expressing mutated tau compared to controls. Can the authors comment on these aspects?
This is a very important point and we appreciate being reminded to refer to it. Tau mutations are known to cause neural death, which would reduce hnRNP labeling since there are fewer neurons in the section. However, the remaining cells express hnRNPs; we suspect that this is why we did not see in this model the overwhelming decline observed in the AD brain. This is actually a further verification that neuronal death is not the underlying mechanisms resulting in reduced hnRNP A/B expression in AD. A note to this effect has been added to the revised manuscript.
6 -Finally, the authors consider the fact that AD brains are characterized by cholinergic defects (from point 5 we should assume that a cholinergic defect is not induced upon expressing mutated Tau). They induce in vivo loss of function by destroying cholinergic neurons. It is unclear to me if this treatment affects only the expression of hnRNP A/B or other splicing factors as well. Moreover, the effect of these treatments on the expression of hnRNP proteins appears more modest than that observed in patients (compare the histogram in panel 5C with those in panel 2C). It would be nice to see whether the same alterations in AS profiles observed after pharmacological treatments do occur in mice after down-regulation of hnRNP A/B proteins.
We have now checked the level of the SR splicing factors and show in the supplementary data that no significant change occurs in the brain upon depletion of cholinergic neurons.
2nd Editorial Decision 30 March 2012
Thank you for the submission of your manuscript to EMBO Molecular Medicine. We have now heard back from the three referees whom we asked to re-evaluate your manuscript.
As you can see from the enclosed reports, while referee 2 is now satisfied and supports publication, referees #1 and #3 feel that some of their initial concerns were not fully addressed.
As Referee #3 remains globally supportive, I would like to give you another chance to address the remaining issues as convincingly as possible.
Please be aware that depending on the revised version, the manuscript may be sent out for review once more.
I would appreciate if you could address these concerns as quickly as possible.
Yours sincerely,
Editor EMBO Molecular Medicine ***** Reviewer's comments ***** Referee #1:
The revised version of the manuscript does not exhaustively answer several points raised in the previous evaluation, as detailed below, referring to the numbers of previous evaluation. 1. Splicing alterations.... 1a -AChE is a well known case of alternative splicing, which brings about a different cellular localization of the protein, as stated in the sentence added on p. 11, but not directly loss of protein function.. One wonders how replacement of the AChE-S variant with AChE-R variant leads to lower AChE level in the culture medium of neurons in which hnRNP A/B has been lowered (Fig. 5) ; as a matter of fact one could expect the contrary, since R variant is not membrane bound. It may be added that no information is given in the Method Section on culture conditions and timing of medium collection for AChE assay. 1b -Marked lower levels are reported in fig 5H for two proteins relevant for synapse formation, synaptophysin and neuroligin 3. How is this related to loss of hnRNP? Has differential splicing for neuroligin 3 been reported (?). These points have not been considered in the revised version.
2. The observation that Parkinson is not related to hnRNP A/B in my opinion strengthen the opportunity to include experiments with toxin specifically directed to dopaminergic neurons e.g. MPTP, which have been used to obtain animal models of Parkinson. Fig. 5 (present version) The use of "synaptic-like structure" instead of "synapse" eludes the point raised in the comment, which suggested the use of more appropriate synapse markers, if AA want to underline impairment of synapse formation, in addition to reduced dendrite formation. Sample frame(s) of microscopic fields used for normalization to nuclei number should be shown.
Data shown in
Referee #2:
the authors have most satisfactorily addressed all my concerns, including data from more patients and of different pathologies (epilepsy), re-grouped existing cases, established a collaboration to rule out disease un-specificity, new biochemistry and immunocytochemical experiments, re-discussion about the relevance of ApoE contribution, toned down clinical relevance: everything I requested was most appropriately addressed: my sincere congratulations to the authors. Given the above and the novelty of the results I do now find the current version of this work suitable for publication at EMBO Molecular Medicine.
Referee #3:
I am still convinced that this is an interesting manuscript that investigates the so far underestimated role of alternative splicing (AS) in sporadic Alzheimer's disease (AD).
Some aspects must be addressed.
New point: Zearfoss and collaborators have recently shown that the level of hnRNP A1 is controlled by Quaking (Qk), another RNA binding protein. Qk mutation destabilizes hnRNP A1 mRNA and this event is crucially linked to psychiatric diseases. Both proteins (hnRNP A1 and Qk) are involved in myelin gene expression. Notably, down-regulation of hnRNP A1 affects splicing decision leading to down-regulation of 93 exons and up-regulation of 70 exons, a frequency that differs from that reported in this manuscript. Moreover, hnRNP A1 has been shown by others to control the level of hnRNP A2 by promoting splicing of an intron in the 3'UTR, which results in NMD mediated mRNA degradation. It is unclear whether similar splicing events coupled to NMD are occurring in the experimental system studied here. The author should comment on these aspects to better describe their system. Moreover they should add references for these publications.
Concerning my previous points. 1 -It would be nice to know the level of concordance between the 3 analyzed patients.
I agree with the authors' answer (A group of three is too small for elaborate statistics). However, in order to support their conclusion that splicing alterations are indeed associated with hnRNP A2/A1 levels rather than being individual variations it would be interesting to know which is the fraction of exons whose splicing is affected in all patients.
-
The authors should investigate the effect of hnRNP A/B depletion on the alternative splicing profile of selected genes as in Figure 1 and 5. This is important to better understand the experiments in Figure 5 . Moreover, to substantiate the role of hnRNP A/B proteins in the alterations of AS profiles they should experimentally prove the interaction of these proteins with target RNAs. Minimally they should identify possible binding sites by in silico analysis.
I am not really satisfied with the authors answer (We analyzed alternative splicing of several selected transcripts following the knock-down of hnRNP A1, A2/B1 in primary neurons. We now show that this depletion results in increased exon inclusions in 3 alternative exons in the mRNA transcripts of Dystonin, DRAM2 and ApoeR2. This result is included in the new Figure 5 of the revised manuscript). First of all, they do not provide any image of the RT-PCR analysis to show the effect of hnRNP downregulation on the splicing profile of the indicated genes nor they specify in the figure legend how the analysis has been performed (conventional RT-PCR vs real time). Moreover, the behavior of DRAM2 appears to be different from that in Figure 1 . In figure 1 there is an almost complete shift in the inclusion vs skipping ratio while in Figure 5 the difference is 1.5 fold. Even more difference is observed with the remaining genes. Thus, one should conclude that additional factors are involved (see also the Qk comment on new point). Finally, no evidence is provided to suggest that the alteration in the splicing profile of the selected genes is directly dependent on hnRNP A1/A2 binding. I am perfectly aware that the experimental demonstration of this point can be time consuming. Thus, I suggested to make an in silico search for putative binding sites as a minimal indication in support of the authors' interpretation. I think that this analysis is relevant for the conclusion that hnRNP A1/A2 promote exon inclusion. Indeed, it is formally possible that the alteration can reflect the different expression of another splicing factor controlled by hnRNP proteins.
6 Moreover, the effect of these treatments on the expression of hnRNP proteins appears more modest than that observed in patients (compare the histogram in panel 5C with those in panel 2C). It would be nice to see whether the same alterations in AS profiles observed after pharmacological treatments do occur in mice after down-regulation of hnRNP A/B proteins. The authors do not address this point. However it emerges from their data that at least in the case of DSTE41, DRAME2 and RELN genes the effect is clearly different from that observed both in patients and after siRNA mediated down-regulation of hnRNP proteins. The revised version of the manuscript does not exhaustively answer several points raised in the previous evaluation, as detailed below, referring to the numbers of previous evaluation. (Fig. 5) ; as a matter of fact one could expect the contrary, since R variant is not membrane bound. It may be added that no information is given in the Method Section on culture conditions and timing of medium collection for AChE assay.
Thank you for drawing our attention to this lack of information. Bernard Jasmin and colleagues have actually shown that both the AChE-R mRNA and the AChE-R protein are considerably less stable than the major AChE-S mRNA and its AChE-S protein product (Chan et al., 1998) , and that in brain neurons, this is most likely due to the activities of the RNA-binding HuD protein (Deschenes-Furry et al., 2007) . This is explained in the re-revised manuscript, and the new reference is cited. Additionally, the Methods section had been expanded to include the requested details.
Deschenes-Furry, J.L., Mousavi, K., Bolognani, F., Neve, R.L., Parks, R.J., Perrone-Bizzozero, N. and Jasmin, B.J. The RNA-binding protein HuD binds to AChE mRNA in neurons and regulates its expression following axotomy. J. Neurosci. Having demonstrated the absence of hnRNPs decline in authentic Parkinson's brain tissues, we surmised that going back to experimental animals to re-explore this negative control may add very little. Also, the MPTP experiments are high risk ones and lethal to the animals and hence difficult and slow to approve at the relevant committees. Nevertheless, MPTP also operates as an AChE inhibitor, and cholinergic impairments increase the risk of Parkinsonism in humans and mice alike: we have recently shown that over-expression of the 'synaptic' AChE-S variant exacerbates MPTP sensitivity, whereas enforced excess of the soluble AChE-R splice variant exerts neuroprotection from MPTP (both in press in Soreq et al., Neurobiology of Disease 2012; Ben-Moyal-Segal et al., Neurodegenerative disease 2012). To rapidly gain new insights into the potential role of hnRNPs in the cholinergic contribution to Parkinsonism, we tested hippocampal RNA preparations from the brain of engineered model mice. In line with our current study, RT-PCR tests showed considerably higher levels of hnRNP A1, A2/B1 and A3 in the hippocampi from the protected TgR overexpressors of AChE-R as compared to the vulnerable TgS over-expressors of AChE-S. Thus, hnRNPs appear not to be grossly depleted from the parkinsonian brain, but are induced by the cholinergic reaction to dopaminergic poisons. These new findings were included in a new supplementary file and mentioned in the text. Fig. 5 (present version) The use of "synaptic-like structure" instead of "synapse" eludes the point raised in the comment, which suggested the use of more appropriate synapse markers, if AA want to underline impairment of synapse formation, in addition to reduced dendrite formation.
Data shown in
Thanks for drawing our attention to the unclear phrasing of our results. The numbers of affected exons (marked as 'events') that are shown in Figure 1B for each group of exons as per the fold change differences refers to changes found in all analyzed patients versus controls. Thus, there were over 100 exon inclusions in those transcripts where the splice index was changed by 1.2-fold, over 70 other exon inclusions in the group of transcripts where the splice index was changed by 1.4-fold etc. Altogether, over 70% of the disease-relevant splicing events that were detected were inclusions. In spite of the small group size, the observed differences were statistically significant, which implies that the results were rather close in each patient and each control sample. Figure 1 and 5. This is important to better understand the experiments in Figure 5 . Moreover, to substantiate the role of hnRNP A/B proteins in the alterations of AS profiles they should experimentally prove the interaction of these proteins with target RNAs. Minimally they should identify possible binding sites by in silico analysis.
-The authors should investigate the effect of hnRNP A/B depletion on the alternative splicing profile of selected genes as in
This analysis has been done as requested, with particular emphasis on the high-affinity binding sites for hnRNP A1 as identified in the 1994 Burd and Dryfuss EMBO Journal article. We found that each of the 6 example transcripts includes Many such high affinity binding sites and detected several of those at both margins of the included exons. This information, and the reference were now included in the re-revised manuscript.
I am not really satisfied with the authors' answer (We analyzed alternative splicing of several selected transcripts following the knockdown of hnRNP A1, A2/B1 in primary neurons. We now show that this depletion results in increased exon inclusions in 3 alternative exons in the mRNA transcripts of Dystonin, DRAM2 and ApoeR2. This result is included in the new Figure 5 of the revised manuscript). First of all, they do not provide any image of the RT-PCR analysis to show the effect of hnRNP downregulation on the splicing profile of the indicated genes nor they specify in the figure legend how the analysis has been performed (conventional RT-PCR vs real time).
We apologize; this analysis has been performed using real-time RT-PCR, where threshold cycles are used to calculate relative amounts of individual exon levels. Normalizing the levels of the alternative exon to that of a constitutive exon was routinely included in all of these tests, which ruled out any possible effect of global transcript levels. Given that Real-time and not a gel-based analysis has been performed, no such image is available. We thank the reviewer for raising this point that is now corrected in the figure legend.
Moreover, the behavior of DRAM2 appears to be different from that in Figure 1 . In figure 1 there is an almost complete shift in the inclusion vs skipping ratio while in Figure 5 the difference is 1.5 fold. Even more difference is observed with the remaining genes. Thus, one should conclude that additional factors are involved (see also the Qk comment on new point). Finally, no evidence is provided to suggest that the alteration in the splicing profile of the selected genes is directly dependent on hnRNP A1/A2 binding. I am perfectly aware that the experimental demonstration of this point can be time consuming. Thus, I suggested to make an in silico search for putative binding sites as a minimal indication in support of the authors' interpretation. I think that this analysis is relevant for the conclusion that hnRNP A1/A2 promote exon inclusion. Indeed, it is formally possible that the alteration can reflect the different expression of another splicing factor controlled by hnRNP proteins.
We definitely agree, and referred to this difference between the human and mouse data, to the Qk story and to the fact that the exon inclusion effect may be indirect through another hnrNP-regulated splicing factor in the revised manuscript.
6 Moreover, the effect of these treatments on the expression of hnRNP proteins appears more modest than that observed in patients (compare the histogram in panel 5C with those in panel 2C). It would be nice to see whether the same alterations in AS profiles observed after pharmacological treatments do occur in mice after down-regulation of hnRNP A/B proteins. The authors do not address this point. However it emerges from their data that at least in the case of DSTE41, DRAME2 and RELN genes the effect is clearly different from that observed both in patients and after siRNA mediated down-regulation of hnRNP proteins.
We understand and appreciate this concern, and refer in the revised manuscript to the differences between the tested experimental mice, where no cell death took place and the advanced Alzheimer's patients where massive loss of neurons has already occurred.
